Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Company Deals

CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy

Fineline Cube Jun 16, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...

Company Deals Hospital

Raffles Medical Partners with CQMU First Hospital to Enhance Healthcare Services

Fineline Cube Jun 16, 2025

Singapore-based Raffles Medical Group, a leading integrated healthcare provider with a broad presence in Asia,...

Company Deals

AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...

Company Deals

CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments

Fineline Cube Jun 16, 2025

China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...

Company Deals

Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development

Fineline Cube Jun 16, 2025

Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...

Company Deals

Nona Biosciences Licenses HCAb Technology to Visterra for Biologic Development

Fineline Cube Jun 13, 2025

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with...

Company Deals

BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies

Fineline Cube Jun 13, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...

Company Drug

AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults

Fineline Cube Jun 13, 2025

US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...

Company Drug

Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment

Fineline Cube Jun 13, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...

Company Deals

GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries

Fineline Cube Jun 13, 2025

UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an...

Company Drug

Merck Launches Phase III Trial for Quadrivalent Dengue Vaccine V181

Fineline Cube Jun 13, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III...

Company Deals

NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery

Fineline Cube Jun 13, 2025

US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo...

Company Drug

Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial

Fineline Cube Jun 13, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced positive results from a Phase II study of...

Company Deals

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research

Fineline Cube Jun 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a...

Company Deals

Bayzed Health Launches HK IPO to Expand Cancer Care Services

Fineline Cube Jun 13, 2025

China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...

Company Deals

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share

Fineline Cube Jun 13, 2025

China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...

Company Drug

BeOne Medicines Wins FDA Approval for Brukinsa Tablet Across All Five Indications

Fineline Cube Jun 13, 2025

China-based BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced that it has received...

Company Deals Medical Device

Gene Solutions Partners with Topgen Biopharm to Advance Precision Oncology in Asia

Fineline Cube Jun 13, 2025

Vietnam-based Gene Solutions, a provider of genetic tests and non-invasive prenatal testing (NIPT) for women’s...

Company Deals

Suzhou’s MEI Medical Secures RMB 100M Funding for ePTFE Innovation

Fineline Cube Jun 13, 2025

Suzhou-based MEI Medical Technologies Co., Ltd., a medical device manufacturer specializing in peripheral vascular intervention,...

Company Drug

BMS Reports Positive POETYK PsA-1 Results for Sotyktu in Psoriatic Arthritis

Fineline Cube Jun 13, 2025

US-based Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive results from the pivotal Phase III POETYK...

Posts pagination

1 … 101 102 103 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.